The complex pharmaceutical supply chain is ripe for disruption from all angles. Here's how startups are leveraging tech to simplify the process of prescribing and delivering medication.
We look into some of the top companies, investors, and acquirers focused on treatments for rare diseases, from immune system deficiencies to respiratory diseases.
The cardiovascular device market is a crucial part of the larger medical device industry. Here, we break down which categories within the space are attracting the most attention based on patent applications and earnings calls mentions.
New approaches to drug R&D are crucial to discovering novel therapeutic candidates. Big pharma companies are looking to artificial intelligence startups for innovative solutions.
Gene-editing technology CRISPR has taken hold of the biotech world with its long list of potential applications, from curing sickle cell disease to engineering new agricultural crops. We look at who’s investing in this technology and what areas are attracting the most interest.
Led by BPI France and Temasek Holdings, a number of top sovereign wealth funds have increased their healthcare investments over the past five years.
Reports suggest Walmart is looking to Humana for a deeper partnership or an outright buyout as the healthcare consolidation sprees continue. PillPack is another acquisition target for the retail giant. Earnings transcript reports suggest that Walmart held its healthcare ambitions close to its chest while Wall Street appeared to miss the possible connection.